Prevention of liver metastasis after resection of colorecatal cancer using immunoconjugates composed of anticancer drug and chimeric antibody

点击翻译按钮获取中文摘要

The goal of this study is to develop a new type of targeting chemotherapy using human/mouse chimeric monoclonal antibody and anticancer drug and to apply it for the prevention of hepatic metastasis after curative resection of colorectal cancer. Through the phase I clinical study, maximum tolerance dose of this immunoconjugate could be defined and chirneric immunoconjugate showed less antigenicity compared with immunoconjugate composed of mouse monoclonal antibody. Though, the development of minor reaction of anti-idio type human anti-mouse antibody could not be avoided. The characterization of antigen detected by chimeric antibody is necessary to extend this study, though the characterizations are still in progress. Though the recent change of GCP(good clinical practice) interrupted the permission of clinical trial of this immunoconjugates, application of the phase II clinical study will be authorized near future.